AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22829919 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly sulfadoxine-pyrimethamine and two doses of azithromycin (AZI-SP) among HIV-negative participants
Number of subjects: 484
Study 19605964 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (straight laparoscopic surgery in 92 patients and hand-assisted laparoscopic surgery in 38 patients)
Number of subjects: 130
Study 19605964 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 130
Study 18089908 — intervention group
Group type: EXPERIMENTAL
Intervention: Training (aerobic and strength exercises)
Number of subjects: 16
Study 18089908 — intervention group
Group type: COMPARATOR
Intervention: Nontraining
Number of subjects: 16
Study 15149550 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced endoscopists
Number of subjects: 10
Study 15149550 — intervention group
Group type: COMPARATOR
Intervention: Inexperienced endoscopists
Number of subjects: 10
Study 11672499 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke + Distractor
Number of subjects: 45
Study 11672499 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke + No Distractor
Number of subjects: 45
Study 11672499 — intervention group
Group type: COMPARATOR
Intervention: No Smoke + Distractor
Number of subjects: 45
Study 11672499 — intervention group
Group type: COMPARATOR
Intervention: No Smoke + No Distractor
Number of subjects: 45
Study 9540427 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost 25 micrograms
Number of subjects: 302
Study 9540427 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost 50 micrograms
Number of subjects: 302
Study 9540427 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost 75 micrograms
Number of subjects: 302
Study 9540427 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost 100 micrograms
Number of subjects: 302
Study 9540427 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 302
Study 9329511 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (750 mg daily for 8 weeks)
Number of subjects: 100
Study 9329511 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (bismuth subcitrate 120 mg, tetracycline 500 mg, metronidazole 400 mg, each given orally four times daily for 1 week) followed by naproxen (750 mg daily for 8 weeks)
Number of subjects: 100
Study 2663937 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketanserin (2% ointment)
Number of subjects: 72
Study 2663937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 194691 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (cyclophosphamide, methotrexate, CCNU)
Number of subjects: 32
Study 194691 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose chemotherapy (cyclophosphamide, methotrexate, CCNU)
Number of subjects: 32
Study 194691 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 32
Study 31743533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine 0.25 mg/kg preoperatively, followed by 0.25 mg/kg/hr intraoperatively, and 0.1 mg/kg/hr from 1 hr before the end of surgery until the end of recovery room stay
Number of subjects: 160
Study 31743533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 31422685 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrosis homogenization as second procedure for group 1 (AF recurrence)
Number of subjects: 102
Study 31422685 — intervention group
Group type: EXPERIMENTAL
Intervention: LGE‐MRI‐detected scar‐based dechanneling for group 2 (AT recurrence)
Number of subjects: 102
Study 31422685 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroanatomically guided dechanneling in group 2
Number of subjects: 102
Study 31422685 — intervention group
Group type: EXPERIMENTAL
Intervention: LGE‐MRI based dechanneling in group 2
Number of subjects: 102
Study 27830456 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 32
Study 27830456 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 32
Study 27830456 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine
Number of subjects: 32
Study 26076867 — intervention group
Group type: EXPERIMENTAL
Intervention: avibactam 500 mg
Number of subjects: 16
Study 26076867 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftazidime 2000 mg plus avibactam 500 mg
Number of subjects: 16
Study 26076867 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 23260506 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician management plus cognitive behavioral therapy
Number of subjects: 141
Study 23260506 — intervention group
Group type: COMPARATOR
Intervention: Physician management
Number of subjects: 141
Study 22980100 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based psychosocial intervention consisting of 12 sessions (30 minutes of relaxation exercises and 75 minutes of structured support groups) delivered twice per week over six weeks.
Number of subjects: 0
Study 19328348 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronystagmography testing
Number of subjects: 20
Study 19328348 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 20
Study 16452734 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction and fixation
Number of subjects: 207
Study 16452734 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar hemiarthroplasty with cement
Number of subjects: 207
Study 16452734 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip replacement with cement
Number of subjects: 207
Study 16452734 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 207
Study 15361773 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol bolus (0.1, 0.25, 0.5, 1.0 and 2.0 microg/m)
Number of subjects: 38
Study 15361773 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion (10, 20 and 40 ng/kg per min for 30 min)
Number of subjects: 38
Study 15361773 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline heart rate
Number of subjects: 38
Study 15361773 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary noradrenaline
Number of subjects: 38
Study 15361773 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma noradrenaline
Number of subjects: 38
Study 11220439 — intervention group
Group type: EXPERIMENTAL
Intervention: Power primed communals
Number of subjects: 0
Study 11220439 — intervention group
Group type: EXPERIMENTAL
Intervention: Power primed exchangers
Number of subjects: 0
Study 9863121 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbs combined with chemotherapy
Number of subjects: 167
Study 9863121 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (Control)
Number of subjects: 167
Study 8296357 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated bed net (PIB)
Number of subjects: 341
Study 8296357 — intervention group
Group type: EXPERIMENTAL
Intervention: Family size non-impregnated bed net (FNIB)
Number of subjects: 341
Study 8296357 — intervention group
Group type: COMPARATOR
Intervention: Non-impregnated bed net (NIB)
Number of subjects: 341
Study 8296357 — intervention group
Group type: COMPARATOR
Intervention: No net
Number of subjects: 341
Study 3528087 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + MISO (400 mg/M2 2‐4 hours prior to RT daily, maximum 12 gm/M2)
Number of subjects: 120
Study 3528087 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 120
Study 3528087 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + MISO
Number of subjects: 120
Study 28404217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingroup members
Number of subjects: 0
Study 28404217 — intervention group
Group type: EXPERIMENTAL
Intervention: Outgroup members
Number of subjects: 0
Study 28404217 — intervention group
Group type: EXPERIMENTAL
Intervention: Social group membership
Number of subjects: 0
Study 28404217 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger children (3-6 years)
Number of subjects: 0
Study 27531289 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified phaco capsulotomy technique
Number of subjects: 80
Study 27531289 — intervention group
Group type: COMPARATOR
Intervention: High-viscosity OVD–assisted capsulorhexis (sodium hyaluronate 2.0%)
Number of subjects: 80
Study 24045440 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by local therapy (radiation and/or surgery) and adjuvant chemotherapy
Number of subjects: 32
Study 24045440 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy/surgery alone
Number of subjects: 32
Study 24045440 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy only
Number of subjects: 32
Study 24045440 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiochemotherapy/surgery
Number of subjects: 32
Study 24045440 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryonal histology
Number of subjects: 32
Study 24045440 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar histology
Number of subjects: 32
Study 24045440 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal incontinence
Number of subjects: 32
Study 24045440 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QOL)
Number of subjects: 32
Study 22562409 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 234
Study 22562409 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 234
Study 20949292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative microelectrode recording (MER) during STN-DBS
Number of subjects: 85
Study 20949292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative microelectrode recording (MER) during GPi-DBS
Number of subjects: 85
Study 20949292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative test stimulation
Number of subjects: 85
Study 20949292 — intervention group
Group type: EXPERIMENTAL
Intervention: Final electrode location selection based on MER activity
Number of subjects: 85
Study 20949292 — intervention group
Group type: EXPERIMENTAL
Intervention: MER activity intensity
Number of subjects: 85
Study 20949292 — intervention group
Group type: EXPERIMENTAL
Intervention: Macro-test stimulation
Number of subjects: 85
Study 18564626 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (45 mg on day 2, 90 mg on day 3)
Number of subjects: 65
Study 18564626 — intervention group
Group type: COMPARATOR
Intervention: Placebo (day 1)
Number of subjects: 65
Study 16033730 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine (premeal)
Number of subjects: 860
Study 16033730 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine (postmeal)
Number of subjects: 860
Study 16033730 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (premeal)
Number of subjects: 860
Study 12472702 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital (10 mg.ml‐1) combined with remifentanil (6.67 micro g.ml‐1)
Number of subjects: 162
Study 12472702 — intervention group
Group type: COMPARATOR
Intervention: Propofol and fentanyl
Number of subjects: 162
Study 10051728 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FP) 200 microg once daily for 4 weeks
Number of subjects: 16
Study 10051728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10051728 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FP)
Number of subjects: 16
Study 7572828 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-designed jobs and supportive workplace relationships and policies
Number of subjects: 0
Study 7572828 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal sources of support
Number of subjects: 0
Study 7572828 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal sources of support
Number of subjects: 0
Study 7572828 — intervention group
Group type: EXPERIMENTAL
Intervention: African American workers, especially women
Number of subjects: 0
Study 2140546 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (two 250 mg tablets twice daily)
Number of subjects: 120
Study 2140546 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (two 500 mg capsules twice daily)
Number of subjects: 120
Study 498423 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin on day 1 + ARA‐C on days 1‐5
Number of subjects: 44
Study 498423 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin on days 1 and 2 + ARA‐C on days 4‐8
Number of subjects: 44
Study 498423 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin-DNA complex on days 1‐2 + ARA‐C on days 4‐8
Number of subjects: 44
Study 31136470 — intervention group
Group type: EXPERIMENTAL
Intervention: Projection method
Number of subjects: 60
Study 31136470 — intervention group
Group type: COMPARATOR
Intervention: Doppler method
Number of subjects: 60
Study 28892233 — intervention group
Group type: EXPERIMENTAL
Intervention: HA microneedle patch
Number of subjects: 34
Study 28892233 — intervention group
Group type: COMPARATOR
Intervention: HA essence application
Number of subjects: 34
Study 26202042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling intervention to maintain normothermia (36.5‐37 °C) during 48 hours.
Number of subjects: 197
Study 26202042 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent with a temperature below 38.4 °C during the cooling intervention.
Number of subjects: 197
Study 26202042 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent with a heart rate below 95 b/min during the cooling intervention.
Number of subjects: 197
Study 26202042 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent with a temperature below 38.4 °C as a mediator of mortality.
Number of subjects: 197
Study 23689006 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization treatment with calcium hydroxide
Number of subjects: 34
Study 23689006 — intervention group
Group type: COMPARATOR
Intervention: Conventional apexification procedures (Control)
Number of subjects: 34
Study 21747052 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest-carbohydrate diet
Number of subjects: 738
Study 21747052 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest-carbohydrate diet
Number of subjects: 738
Study 19269895 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant and adjuvant temozolomide with radiotherapy
Number of subjects: 573
Study 19269895 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 573
Study 17110006 — intervention group
Group type: EXPERIMENTAL
Intervention: One miniplate
Number of subjects: 62
Study 17110006 — intervention group
Group type: COMPARATOR
Intervention: Two miniplates
Number of subjects: 62
Study 14742382 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl HCl PCTS 40 microg
Number of subjects: 205
Study 14742382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 11367972 — intervention group
Group type: COMPARATOR
Intervention: Listerine Antiseptic (L)
Number of subjects: 316
Study 11367972 — intervention group
Group type: COMPARATOR
Intervention: Colgate Total toothpaste (T)
Number of subjects: 316
Study 11367972 — intervention group
Group type: EXPERIMENTAL
Intervention: Control toothpaste/control rinse (P)
Number of subjects: 316
Study 9406261 — intervention group
Group type: EXPERIMENTAL
Intervention: System of care services
Number of subjects: 350
Study 9406261 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 350
Study 8428561 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete alcohol abstinence for one year
Number of subjects: 30
Study 8428561 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuming alcohol abuse
Number of subjects: 30
Study 3595068 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting (10 mg nifedipine)
Number of subjects: 15
Study 3595068 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat meal (10 mg nifedipine)
Number of subjects: 15
Study 3595068 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (10 mg nifedipine)
Number of subjects: 15
Study 31886707 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone implant
Number of subjects: 60
Study 31886707 — intervention group
Group type: COMPARATOR
Intervention: Oral acetazolamide (500 mg/day)
Number of subjects: 60
Study 30176845 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic self-monitoring (5 times per day) and weekly personalized feedback on positive affect and activities ("Do"-module)
Number of subjects: 150
Study 30176845 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic self-monitoring (5 times per day) and weekly personalized feedback on negative affect and thinking patterns ("Think"-module)
Number of subjects: 150
Study 30176845 — intervention group
Group type: COMPARATOR
Intervention: No additional intervention (control group)
Number of subjects: 150
Study 27229682 — intervention group
Group type: EXPERIMENTAL
Intervention: Let's Move It intervention (group sessions, poster campaign, sitting reduction, enhancement of PA opportunities)
Number of subjects: 57
Study 27229682 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard curriculum)
Number of subjects: 57
Study 27229682 — intervention group
Group type: EXPERIMENTAL
Intervention: Let's Move It intervention
Number of subjects: 57
Study 25239716 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter use noted in postadmission records
Number of subjects: 294
Study 25239716 — intervention group
Group type: EXPERIMENTAL
Intervention: NHSN symptoms noted
Number of subjects: 294
Study 25239716 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential NHSN CAUTI
Number of subjects: 294
Study 24407896 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with TCI (Group A)
Number of subjects: 337
Study 24407896 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced anaesthesia (Group B)
Number of subjects: 337
Study 24407896 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced anaesthesia (Group C)
Number of subjects: 337
Study 24407896 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced anaesthesia (Group D)
Number of subjects: 337
Study 21312290 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (100-150 mg/day depending on weight)
Number of subjects: 40
Study 21312290 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (20-30 mg/day)
Number of subjects: 40
Study 18186057 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological/genetic explanation of anorexia nervosa
Number of subjects: 0
Study 18186057 — intervention group
Group type: COMPARATOR
Intervention: Sociocultural explanation of anorexia nervosa
Number of subjects: 0
Study 16817177 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg abciximab bolus administered early in the emergency department
Number of subjects: 80
Study 16817177 — intervention group
Group type: COMPARATOR
Intervention: 0.25 mg/kg abciximab bolus administered late in the catheterization laboratory
Number of subjects: 80
Study 12538427 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine infusion
Number of subjects: 39
Study 12538427 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA (NO synthase inhibitor)
Number of subjects: 39
Study 12538427 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside infusion
Number of subjects: 39
Study 12538427 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA
Number of subjects: 39
Study 12538427 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular cell adhesion molecule-1
Number of subjects: 39
Study 10887714 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Pain Self‐Management Program (CPSMP)
Number of subjects: 110
Study 8882255 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg intrathecal morphine
Number of subjects: 50
Study 8882255 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg intrathecal morphine
Number of subjects: 50
Study 1658648 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange twice weekly for three weeks
Number of subjects: 39
Study 1658648 — intervention group
Group type: COMPARATOR
Intervention: Sham plasma exchange
Number of subjects: 39
Study 1658648 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange in open trial after sham exchange
Number of subjects: 39
Study 6395905 — intervention group
Group type: EXPERIMENTAL
Intervention: Group progressive relaxation training
Number of subjects: 45
Study 6395905 — intervention group
Group type: COMPARATOR
Intervention: Individual EMG biofeedback training
Number of subjects: 45
Study 6395905 — intervention group
Group type: COMPARATOR
Intervention: Placebo group listening to taped children's stories
Number of subjects: 45
Study 31758382 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential currents (IFC)
Number of subjects: 52
Study 31758382 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 52
Study 30779333 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART-based treatment (online lessons, self-monitoring, feedback, monthly weigh-ins)
Number of subjects: 276
Study 30779333 — intervention group
Group type: EXPERIMENTAL
Intervention: GROUP-based treatment (weekly meetings for 6 months, biweekly for 6 months, monthly for 6 months, self-monitoring via paper diaries with written feedback)
Number of subjects: 276
Study 30779333 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (self-monitoring via paper diaries with written feedback and monthly weigh-ins)
Number of subjects: 276
Study 28134840 — intervention group
Group type: EXPERIMENTAL
Intervention: A2 milk (500 mL)
Number of subjects: 21
Study 28134840 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular milk (500 mL)
Number of subjects: 21
Study 28134840 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) (500 mL)
Number of subjects: 21
Study 28134840 — intervention group
Group type: EXPERIMENTAL
Intervention: A2 milk
Number of subjects: 21
Study 28134840 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular milk
Number of subjects: 21
Study 28134840 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk treatments (A2 and regular)
Number of subjects: 21
Study 25856225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 150 mg monthly
Number of subjects: 69
Study 25856225 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 35 mg weekly
Number of subjects: 69
Study 25856225 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 69